Rather, the cross-claimants have had the benefit of the patents for a long time, and the cross-respondent now proposes to enter the market for gemcitabine-based pharmaceuticals. The question is: what did the specification promise? 27 Apotex Pty Ltd v Sanofi-Aventis [2008] FCA 194 involved an application for revocation upon the ground that the patent, which claimed an enantiomer, was disclosed by earlier publications which were said to involve racemic mixtures only. 57 See confidential annexure. Nfg.KG ("EBEWE"). The cross-claimants also notified the cross-respondent of the existence, and the relevance, of the process patent.